The Biden administration has generated a list of 48 drugs whose prices were raised faster than inflation in the last quarter of this year and may be subject to the mandato
A proposal by the US Department of Health and Human Services (HHS) would expose the actual costs of drugs covered by Medicaid, and hold manufacturers to account for the am
The 2019 Voluntary Scheme for Branded Medicines Access and Pricing (VPAS) saw the industry agreeing to make payments to the Department of Health and Social Care (DHSC).
As a successor to the 2019 Voluntary Scheme for Branded Medicines Access and Pricing is being negotiated, Leela Barham asks where rebates should go in future - that is, if rebates remain at
After patients enrol in clinical trials, regular assessments and testing – often requiring clinic visits – can become onerous and reduce the chances they will stick with t
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.